Feifei Mao - Publications

CCT3 Enhances Lung Adenocarcinoma Progression by Promoting p53 Ubiquitination and Degradation.

Journal: Medicina (Kaunas, Lithuania)

Published: June 06, 2026

TRNP1 regulates tumorigenesis and enhances immunotherapy response via c-Kit/STAT3 signaling in hepatocellular carcinoma.

Journal: Journal of gastrointestinal oncology

Published: December 28, 2025

New insights into neoadjuvant immunotherapy and chemotherapy combination for resectable N1/N2 NSCLC.

Journal: International journal of surgery (London, England)

Published: September 16, 2025

Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study.

Journal: Signal transduction and targeted therapy

Published: January 15, 2023

Mechanism Research and Application for Ginsenosides in the Treatment of Hepatocellular Carcinoma.

Journal: BioMed research international

Published: October 26, 2022

Transarterial chemoembolization plus immune checkpoint inhibitor as postoperative adjuvant therapy for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter cohort study.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: October 10, 2022

A novel chemotherapy strategy for advanced hepatocellular carcinoma: a multicenter retrospective study.

Journal: Chinese medical journal

Published: September 14, 2022

Mechanistic Insights into the Mechanism of Inhibitor Selectivity toward the Dark Kinase STK17B against Its High Homology STK17A.

Journal: Molecules (Basel, Switzerland)

Published: June 28, 2022

Cuproptosis-related lncRNAs predict the clinical outcome and immune characteristics of hepatocellular carcinoma.

Journal: Frontiers in genetics

Published: June 18, 2022

Analysis of the Heterogeneity of the Tumor Microenvironment and the Prognosis and Immunotherapy Response of Different Immune Subtypes in Hepatocellular Carcinoma.

Journal: Journal of oncology

Published: January 21, 2022

Reveal the Heterogeneity in the Tumor Microenvironment of Pancreatic Cancer and Analyze the Differences in Prognosis and Immunotherapy Responses of Distinct Immune Subtypes.

Journal: Frontiers in oncology

Published: December 10, 2021

Tumor cells derived-extracellular vesicles transfer miR-3129 to promote hepatocellular carcinoma metastasis by targeting TXNIP.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: September 14, 2020